{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000067","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-05-11T20:06:06+00:00","discovered_at":"2026-05-11T20:08:00.325450+00:00","generated_at":"2026-05-11T22:44:40.214186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme Q1 revenue up 42% to $377M; new $1B buyback program","bullets":["Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).","GAAP diluted EPS $1.22 (vs $0.93); Non-GAAP diluted EPS $1.60 (vs $1.11).","New $1B share repurchase program through 2028; at least $400M expected in 2026.","Reiterated 2026 guidance: revenue $1.71B-$1.81B, Non-GAAP EPS $7.75-$8.25.","Collaborations: GSK (multiple oncology ENHANZE targets), argenx VYVGART Hytrulo FDA-approved for all gMG serotypes."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000067","json":"https://secwatch.observer/filing/0001159036-26-000067.json","markdown":"https://secwatch.observer/filing/0001159036-26-000067.md","text":"https://secwatch.observer/filing/0001159036-26-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/0001159036-26-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/halo-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:44:40.214186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec0345d857143f2f9d9fb3f665371e404b9ef319","claim":"HALOZYME THERAPEUTICS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).","evidence_excerpt":"On May 11, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000067/0001159036-26-000067-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}